Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: A possible role for tumor progression

T. Koshiba, R. Hosotani, Y. Miyamoto, J. Ida, Shoichiro Tsuji, S. Nakajima, M. Kawaguchi, H. Kobayashi, R. Doi, T. Hori, N. Fujii, M. Imamura

Research output: Contribution to journalArticle

387 Citations (Scopus)

Abstract

To examine the expression of the stromal cell-derived factor 1 (SDF-1)/CXCR4 receptor ligand system in pancreatic cancer cells and endothelial cells, we performed immunohisto-chemical analysis for 52 pancreatic cancer tissue samples with anti-CXCR4 antibody and reverse transcription-PCR analysis for CXCR4 and SDF-1 in five pancreatic cancer cell lines (AsPC-1, BxPC-3, CFPAC-1, HPAC, and PANC-1), an endothelial cell line (HUVEC), and eight pancreatic cancer tissues. We then performed cell migration assay on AsPC-1 cells, HUVECs, and CFPAC-1 cells in the presence of SDF-1 or MRC-9 fibroblast cells. Immunoreactive CXCR4 was found mainly in pancreatic cancer cells and endothelial cells of relatively large vessels around a tumorous lesion. The immunopositive ratio in the pancreatic cancer was 71.2%. There was no statistically significant correlation with chnicopathological features. SDF-1 mRNA expressions were detected in all pancreatic cancer tissues but not in pancreatic cancer cell lines and HUVECs; meanwhile, CXCR4 mRNA was detected in all pancreatic cancer tissues, cancer cell lines, and HUVECs. The results indicate that the paracrine mechanism is involved in the SDF-1/CXCR4 receptor ligand system in pancreatic cancer. In vitro studies demonstrated that SDF-1 significantly increased the migration ability of AsPC-1 and HUVECs, and these effects were inhibited by CXCR4 antagonist T22, and that the coculture system with MRC-9 also increased the migration ability of CFPAC-1 cells, and this effect was significantly inhibited by T22. Our results suggested that the SDF-1/CXCR4 receptor ligand system may have a possible role in the pancreatic cancer progression through tumor cell migration and angiogenesis.

Original languageEnglish
Pages (from-to)3530-3535
Number of pages6
JournalClinical Cancer Research
Volume6
Issue number9
Publication statusPublished - 26-09-2000

Fingerprint

CXCR4 Receptors
Chemokine CXCL12
Pancreatic Neoplasms
Ligands
Neoplasms
Cell Line
Endothelial Cells
Cell Migration Assays
Messenger RNA
Human Umbilical Vein Endothelial Cells
Coculture Techniques
Reverse Transcription
Cell Movement
Anti-Idiotypic Antibodies
Fibroblasts

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Koshiba, T. ; Hosotani, R. ; Miyamoto, Y. ; Ida, J. ; Tsuji, Shoichiro ; Nakajima, S. ; Kawaguchi, M. ; Kobayashi, H. ; Doi, R. ; Hori, T. ; Fujii, N. ; Imamura, M. / Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer : A possible role for tumor progression. In: Clinical Cancer Research. 2000 ; Vol. 6, No. 9. pp. 3530-3535.
@article{792f7aa2154b4851a1377202115d4528,
title = "Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: A possible role for tumor progression",
abstract = "To examine the expression of the stromal cell-derived factor 1 (SDF-1)/CXCR4 receptor ligand system in pancreatic cancer cells and endothelial cells, we performed immunohisto-chemical analysis for 52 pancreatic cancer tissue samples with anti-CXCR4 antibody and reverse transcription-PCR analysis for CXCR4 and SDF-1 in five pancreatic cancer cell lines (AsPC-1, BxPC-3, CFPAC-1, HPAC, and PANC-1), an endothelial cell line (HUVEC), and eight pancreatic cancer tissues. We then performed cell migration assay on AsPC-1 cells, HUVECs, and CFPAC-1 cells in the presence of SDF-1 or MRC-9 fibroblast cells. Immunoreactive CXCR4 was found mainly in pancreatic cancer cells and endothelial cells of relatively large vessels around a tumorous lesion. The immunopositive ratio in the pancreatic cancer was 71.2{\%}. There was no statistically significant correlation with chnicopathological features. SDF-1 mRNA expressions were detected in all pancreatic cancer tissues but not in pancreatic cancer cell lines and HUVECs; meanwhile, CXCR4 mRNA was detected in all pancreatic cancer tissues, cancer cell lines, and HUVECs. The results indicate that the paracrine mechanism is involved in the SDF-1/CXCR4 receptor ligand system in pancreatic cancer. In vitro studies demonstrated that SDF-1 significantly increased the migration ability of AsPC-1 and HUVECs, and these effects were inhibited by CXCR4 antagonist T22, and that the coculture system with MRC-9 also increased the migration ability of CFPAC-1 cells, and this effect was significantly inhibited by T22. Our results suggested that the SDF-1/CXCR4 receptor ligand system may have a possible role in the pancreatic cancer progression through tumor cell migration and angiogenesis.",
author = "T. Koshiba and R. Hosotani and Y. Miyamoto and J. Ida and Shoichiro Tsuji and S. Nakajima and M. Kawaguchi and H. Kobayashi and R. Doi and T. Hori and N. Fujii and M. Imamura",
year = "2000",
month = "9",
day = "26",
language = "English",
volume = "6",
pages = "3530--3535",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

Koshiba, T, Hosotani, R, Miyamoto, Y, Ida, J, Tsuji, S, Nakajima, S, Kawaguchi, M, Kobayashi, H, Doi, R, Hori, T, Fujii, N & Imamura, M 2000, 'Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: A possible role for tumor progression', Clinical Cancer Research, vol. 6, no. 9, pp. 3530-3535.

Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer : A possible role for tumor progression. / Koshiba, T.; Hosotani, R.; Miyamoto, Y.; Ida, J.; Tsuji, Shoichiro; Nakajima, S.; Kawaguchi, M.; Kobayashi, H.; Doi, R.; Hori, T.; Fujii, N.; Imamura, M.

In: Clinical Cancer Research, Vol. 6, No. 9, 26.09.2000, p. 3530-3535.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer

T2 - A possible role for tumor progression

AU - Koshiba, T.

AU - Hosotani, R.

AU - Miyamoto, Y.

AU - Ida, J.

AU - Tsuji, Shoichiro

AU - Nakajima, S.

AU - Kawaguchi, M.

AU - Kobayashi, H.

AU - Doi, R.

AU - Hori, T.

AU - Fujii, N.

AU - Imamura, M.

PY - 2000/9/26

Y1 - 2000/9/26

N2 - To examine the expression of the stromal cell-derived factor 1 (SDF-1)/CXCR4 receptor ligand system in pancreatic cancer cells and endothelial cells, we performed immunohisto-chemical analysis for 52 pancreatic cancer tissue samples with anti-CXCR4 antibody and reverse transcription-PCR analysis for CXCR4 and SDF-1 in five pancreatic cancer cell lines (AsPC-1, BxPC-3, CFPAC-1, HPAC, and PANC-1), an endothelial cell line (HUVEC), and eight pancreatic cancer tissues. We then performed cell migration assay on AsPC-1 cells, HUVECs, and CFPAC-1 cells in the presence of SDF-1 or MRC-9 fibroblast cells. Immunoreactive CXCR4 was found mainly in pancreatic cancer cells and endothelial cells of relatively large vessels around a tumorous lesion. The immunopositive ratio in the pancreatic cancer was 71.2%. There was no statistically significant correlation with chnicopathological features. SDF-1 mRNA expressions were detected in all pancreatic cancer tissues but not in pancreatic cancer cell lines and HUVECs; meanwhile, CXCR4 mRNA was detected in all pancreatic cancer tissues, cancer cell lines, and HUVECs. The results indicate that the paracrine mechanism is involved in the SDF-1/CXCR4 receptor ligand system in pancreatic cancer. In vitro studies demonstrated that SDF-1 significantly increased the migration ability of AsPC-1 and HUVECs, and these effects were inhibited by CXCR4 antagonist T22, and that the coculture system with MRC-9 also increased the migration ability of CFPAC-1 cells, and this effect was significantly inhibited by T22. Our results suggested that the SDF-1/CXCR4 receptor ligand system may have a possible role in the pancreatic cancer progression through tumor cell migration and angiogenesis.

AB - To examine the expression of the stromal cell-derived factor 1 (SDF-1)/CXCR4 receptor ligand system in pancreatic cancer cells and endothelial cells, we performed immunohisto-chemical analysis for 52 pancreatic cancer tissue samples with anti-CXCR4 antibody and reverse transcription-PCR analysis for CXCR4 and SDF-1 in five pancreatic cancer cell lines (AsPC-1, BxPC-3, CFPAC-1, HPAC, and PANC-1), an endothelial cell line (HUVEC), and eight pancreatic cancer tissues. We then performed cell migration assay on AsPC-1 cells, HUVECs, and CFPAC-1 cells in the presence of SDF-1 or MRC-9 fibroblast cells. Immunoreactive CXCR4 was found mainly in pancreatic cancer cells and endothelial cells of relatively large vessels around a tumorous lesion. The immunopositive ratio in the pancreatic cancer was 71.2%. There was no statistically significant correlation with chnicopathological features. SDF-1 mRNA expressions were detected in all pancreatic cancer tissues but not in pancreatic cancer cell lines and HUVECs; meanwhile, CXCR4 mRNA was detected in all pancreatic cancer tissues, cancer cell lines, and HUVECs. The results indicate that the paracrine mechanism is involved in the SDF-1/CXCR4 receptor ligand system in pancreatic cancer. In vitro studies demonstrated that SDF-1 significantly increased the migration ability of AsPC-1 and HUVECs, and these effects were inhibited by CXCR4 antagonist T22, and that the coculture system with MRC-9 also increased the migration ability of CFPAC-1 cells, and this effect was significantly inhibited by T22. Our results suggested that the SDF-1/CXCR4 receptor ligand system may have a possible role in the pancreatic cancer progression through tumor cell migration and angiogenesis.

UR - http://www.scopus.com/inward/record.url?scp=0033818476&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033818476&partnerID=8YFLogxK

M3 - Article

C2 - 10999740

AN - SCOPUS:0033818476

VL - 6

SP - 3530

EP - 3535

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 9

ER -